Advertisement

Chinese Science Bulletin

, Volume 46, Issue 5, pp 353–358 | Cite as

Bispecific antibody and its clinical applications in cancer

  • Yuanfu Xu
  • Chunzheng Yang
  • Zhenping Zhu
Review
  • 65 Downloads

Abstract

Bispecific antibody (BsAb) usually consists of two different antigen-binding arms, by which it is capable of simultaneously binding to target cells and effector cells, and can directly mediate the killing of target cells by retargeting and activating effector cells. The development of BsAb research goes through three main stages: chemical crosslinking of murine-derived monoclonal antibody, hybrid hybridomas and engineered BsAb. Among them, engineered BsAb has more formats than the other two, such as diabody, ScdHLX, ScZip, ScCH3, ScFab and BsIgG, etc. Compared with former murine-derived BsAbs, engineered BsAb has lower immunogenicity and stronger penetrating capacity, and currently, some of them appear suitable for clinical application in yields and qualities. Up to now, several phase I and phase II clinical studies of BsAb, for instance, some (Fab’)2 and Diabodies, have been performed. Among those BsAbs, anti-CD3/anti-tumor BsAbs is most common, they not only can activate T cell and induce CD3AK cytotoxic activity inin vitro experiment, and inhibit the growth of tumor on tumor-bearing mouse by retargeting T cells to lyse tumor cells, but also offer great promise in the therapy of some malignancies in clinic, especially of some advanced cancers as well as elimination of minimal residual tumors, indicated by increasing the tumor/blood ratio of antibody in patients and improving the natural killer cell (NK) anti-tumor activity in tumor sites, and also presenting of an increase level in TNF-α, INF-γ, IL-6, IL-8, IL-10 and soluble CD25, etc. The responses are also shown via improving the quality of life and prolonging the survival of partial patients. The “Knobs into Holes” technology is a new strategy emerging during research on engineered BsAb, it is likely to be useful for heterodimerization and can improve the quantity, purity and stability of BsAb, it is also anticipated to increase the clinical potential of BsAb in the future.

Keywords

bispecific antibody genetic engineering tumor therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter, P., Ridgway, J., Zhu, Z. P., Toward the production of bispecific antibody fragments for clinical applications, J. Hematother, 1995, 4: 463.Google Scholar
  2. 2.
    Zhu, Z. P., Zapata, G., Shalaby, R. et al., High level secretion of a humanized bispecific diabody fromEscherichia coli, Bio/ technology, 1996, 14: 192.Google Scholar
  3. 3.
    Van de Winkel, G. C., Bast, B. E., Clinical perspectives of bispecific antibodies in cancer, Cancer Immunol. Immunother., 1997, 45: 121.CrossRefGoogle Scholar
  4. 4.
    Brennan, M., Davison, P. F., Paulus, H., Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G’ fragments, Science, 1985, 229: 81.CrossRefGoogle Scholar
  5. 5.
    Shalaby, M. R., Shepard, H. M., Presta, L. et al., Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene, J. Exp. Med., 1992, 175: 217.CrossRefGoogle Scholar
  6. 6.
    Carter, P., Kelley, R. F., Rodrigues, M. L. et al., High levelEscherichia coli expression and production of a bivalent humanized antibody fragment, Bio/Technology, 1992, 10: 163.CrossRefGoogle Scholar
  7. 7.
    Holliger, P., Prospero, T., Winter, G., “Diabodies”: Small bivalent antibody fragment, Proc. Natl. Acid. Sci. USA, 1993, 90: 6444.CrossRefGoogle Scholar
  8. 8.
    Holliger, P., Winter, G., “Diabodies”: Small bivalent antibody fragment, Cancer Immunol. Immunother., 1997, 45: 128.CrossRefGoogle Scholar
  9. 9.
    Fitzgerald, K., Holliger, P., Winter, G., Improved tumor targeting by disulphide stablized diabodies expressed in pichia pastoris, Protein Eng, 1997, 10(10): 1221.CrossRefGoogle Scholar
  10. 10.
    Pack, P., Pluckthun, A., Miniantibodied: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity inEscherichia coli., Biochemistry, 1992, 31: 1579.CrossRefGoogle Scholar
  11. 11.
    Kostelny, S. A., Cole, M. S., Jso, J. Y., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 1992, 148: 1547.Google Scholar
  12. 12.
    Hu, S. Z., Shively, L., Raubitschek, A. et al., Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid high-level targeting of xenografts, Cancer Res., 1996, 56: 3055.Google Scholar
  13. 13.
    Muller, K. M., Arndt, K. M., Strittmatter, W. et al., The first constant domain (CH1 and CL) of an antibody used as herterodimerization domain for bispecific miniantibodies, FEBS Letters, 1998, 422: 259.CrossRefGoogle Scholar
  14. 14.
    Merchant, A. M., Zhu, Z. P., Yuan, J. Q. et al., An efficient route to human bispecific IgG, Nature, Biotechnology, 1998, 16: 677.CrossRefGoogle Scholar
  15. 15.
    Ridgway, J. B., Presta, L. G., Carter, P., “Knobs into holes” engineered of antibody CH3 somains for heavy chain heterodimerization, Protein Eng., 1996, 9: 617.CrossRefGoogle Scholar
  16. 16.
    Canevari, S., Mezzanzanica, D., Menard, S. et al., Possible targets on carcinoma for bMAb retargeting of lymphocyte of drug cytotoxicity, Int. J. Cancer, 1992, supplement 7: 42.Google Scholar
  17. 17.
    Lu, D., Kotanides, H., Jimenez, X. et al., Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2, J. Immunol. Methods, 1999, 230: 159.CrossRefGoogle Scholar
  18. 18.
    Rodrigues, M. L., Shalaby, M. R., Werther, W. et al., Engineered a humanized bispecific F(ab’)2 fragment for improved binding to T cells, Int. J. Cancer, 1992, supplement 7: 45.Google Scholar
  19. 19.
    Manzke, O., Titzer, S., Tesch, H. et al., CD3xCD19 bispecific antibodies and CD28 costimulation for locoregional treatment of tibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma, Cance Immunol. Immunother, 1997, 45: 198.CrossRefGoogle Scholar
  20. 20.
    Kipriyanov, S. M., Moldenhauer, G., Strauss, G. et al., Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cell, Int. J. Cancer, 1998, 7: 763.CrossRefGoogle Scholar
  21. 21.
    Klein, S. C., Boer, L. H., De Weger, R. A. et al., Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 × CD19, Scand. J. Immunol., 1997, 46(5): 452.CrossRefGoogle Scholar
  22. 22.
    Pfosser, A., Brandl, M., Salih, H. et al., Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: apre-clinical study, Int. J. Cancer, 1999, 80(4): 612.CrossRefGoogle Scholar
  23. 23.
    Knuth, A., Bernhard, H., Jager, E. et al., Induction of tumor cell lysis by a bispecific antibody recognising epidermal growth factor receptor(EGFR) and CD3, Eur. J. Cancer, 1994, 30A(8): 1103.CrossRefGoogle Scholar
  24. 24.
    Miotti, S., Negri, D. R., Valota, O. et al., Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival, Int. J. Cancer, 1999, 84(1): 62.CrossRefGoogle Scholar
  25. 25.
    Canevari, S., Mezzanzanica, D., Mazzoni, A. et al., Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions, J. Hematother, 1995, 4(5): 423.Google Scholar
  26. 26.
    Luiten, R. M., Warnaar, S. O., Sanborn, D. et al., Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein(Mov18) and displays decreased immunogenicity in patients, J. Immunother, 1997, 20(6): 496.CrossRefGoogle Scholar
  27. 27.
    Renner, C., Bauer, S., Sahin, U. et al., Cure of disseminated Xenografted human Hodgkin’s tumors by bispecific monoclonal antibodies and human T cell: the role of human T-cell subsets in a preclinical model, Blood, 1996, 87(7): 2930.Google Scholar
  28. 28.
    Helfrich, W., Kroesen, B. J., Roovers, R. C. et al., Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas, Int. J. Cancer, 1998, 76(2): 232.CrossRefGoogle Scholar
  29. 29.
    Kroesen, B. J., Janssen, R. A., Buter, J. et al., Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects, J. Hematother, 1995, 4(5): 409.Google Scholar
  30. 30.
    Kroesen, B. J., Nieken, J., Sleijfer, D. T. et al., Approaches to lung cancer treatment using the CD3 × EGP-2-directed bispecific monoclonal antibody BIS-1, Cancer Immunol. Immunother, 1997, 45(3–4): 203.CrossRefGoogle Scholar
  31. 31.
    Nitta, T., Sato, K., Yagita, H. et al., Preliminary trial of specific targeting therapy against malignant glioma, Lancet, 1990, 335: 368.CrossRefGoogle Scholar
  32. 32.
    Chapoval, A. L., Nelson, H., Thibault, C. et al., Anti-CD3 × anti-tumor F(ab’)2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes, J. Immunol., 1995, 155(3): 1296.Google Scholar
  33. 33.
    Chapoval, A. L., Nelson, H., Thibault, C. et al., Bifunctional antibody retargetingin vivo—activated T lymphocytes: simplifying clinical application, J. Hematother, 1995, 4(6): 571.Google Scholar
  34. 34.
    Kufer, P., Mack, M., Gruber, R. et al., Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer, Cancer Immunol. Immunother, 1997, 45: 193.CrossRefGoogle Scholar
  35. 35.
    Riedle, S., Rosel, M., Zoller, M. et al.,In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice, Int. J. Cancer, 1998, 75(6): 908.CrossRefGoogle Scholar
  36. 36.
    Penna, C., Dean, P. A., Nelson, H., Pulmonary metastases neutralization and tumor rejection byin vivo administration of beta glucan and bispecific antibody, Int. J. Cancer, 1996, 65(3): 377.CrossRefGoogle Scholar
  37. 37.
    Ohta, S., Tsukamoto, H., Watanabe, K. et al., Tumor-associated glycoantigen, sialyl lewis(a) as a target for bispecific antibodydirected adoptive tumor immunotherapy, Immunol. Lett., 1995, 44(2): 35.CrossRefGoogle Scholar
  38. 38.
    Honeychurch, J., Cruise, A., Tutt, A. L. et al., Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in deternining therapeutic outcome, Cancer Immunol. Immunother, 1997, 45: 171.CrossRefGoogle Scholar
  39. 39.
    Porter, L. E., Nelson, H., Gecim, I. E. et al., T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: An effectivein vivo anti-tumor strategy, Cancer Immunol. Immunother, 1997, 45: 180.CrossRefGoogle Scholar
  40. 40.
    De Gast, J. M., Van de Winkel, J. G., Bast, B. E., Clinical perspectives of bispecific antibodies in cancer., Cancer Immunother, 1997, 45: 121.CrossRefGoogle Scholar
  41. 41.
    Dahle, J. E., Weiner, G. J., T-cell activation induced by anti-CD3/ anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand, Cancer Immunol. Immunother, 1997, 45: 174.CrossRefGoogle Scholar
  42. 42.
    Ethem, G. L. E., Chapoval, D. C., T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: An effectivein vivo antitumor strategy, Cancer Immunol. Immunother, 1997, 45: 180.CrossRefGoogle Scholar

Copyright information

© Science in China Press 2001

Authors and Affiliations

  1. 1.National Laboratory of Experiment Hematology, Institute of Hematology, Peking Union Medical CollegeChinese Academy of Medical ScienceTianjinChina

Personalised recommendations